The CJEU, Europe’s highest court, severely restricts availability of Supplementary Protection Certificates (SPCs) for products based on second medical use patents

Ulla Klinge reports On 9 July 2020, the Court of Justice of the European Union (CJEU) handed down its decision in Santen (C-673/18), holding that it is not possible to obtain an SPC for a product based on a marketing authorisation for a new use of a previously-authorised product. Background One of the requirements for ...

read more